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Abstract
Background: Pheochromocytomas (PCC) and paragangliomas (PGL) are neuroendocrine tumours arising from
pluripotent neural crest stem cells and are associated with neurons of the autonomic nervous system. PCCs/PGLs
are often hereditary and multifocal, and their biologic behaviour and metabolic activity vary making imaging of
these tumours challenging. The imaging gold standard has been I-123 MIBG complemented by CT or MRI. PGLs
being neuroendocrine tumours express somatostatin receptors enabling imaging with Ga-68 DOTA-coupled
peptides such as DOTATATE. Imaging with F-18 FDG also provides additional information regarding metabolic
activity and biologic aggressiveness of these tumours, or, in some situations, reflecting metabolic reprogramming of
these tumours. We report our experience using both Ga-68 DOTATATE and F-18 FDG PET/CT imaging in patients
with PGLs and PCCs.
Methods: This was a retrospective review of 23 patients with proven PGL/PCC who underwent both DOTATATE
and FDG PET/CT. Seven patients also had I-123 MIBG SPECT/CT and 1 patient had I-124 MIBG PET/CT. Lesional
intensity and patterns of uptake were analysed.
Results: DOTATATE and FDG were positive at most sites of disease (96.2 % vs 91.4 %), although uptake intensity was
significantly higher on DOTATATE with a median SUV of 21 compared to 12.5 for FDG (p < 0.001). SUVmax on F-18
FDG was significantly higher (p < 0.001) in clinically aggressive cases. I-123/I-124 MIBG detected fewer lesions (30.4 %).
Conclusion: Overall, Ga-68 DOTATATE PET/CT detected similar number but has significantly greater lesion-to-
background contrast compared to F-18 FDG PET/CT. Combined with high specificity, patient convenience and
relatively low cost, DOTATATE PET/CT should be considered the ideal first line investigation for imaging PGL/PCC.
Depending on DOTATATE findings and the clinical question, FDG and MIBG remain useful and, in selected cases, may
provide more accurate staging, disease characterisation and guide treatment choices.
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Background
Paragangliomas (PGL) are neuroendocrine tumours arising
from pluripotent neural crest stem cells and are associated
with neurons of the autonomic nervous system occurring
anywhere along the paravertebral axis from the base of
skull to the pelvis. These can be associated with the sympa-
thetic nervous system and derived from the adrenal me-
dulla, organ of Zuckerkandl or other chromaffin cells that
may persist beyond embryogenesis and, therefore, are more
likely located in the abdomen or pelvis. PGL associated
with the parasympathetic nervous system are derived from
cells in the parasympathetic branchiometric paraganglia
(chemoreceptors) and are mainly located in the head, neck
and mediastinum. Pheochromocytoma (PCC) is reserved
solely for an adrenal paraganglioma according to the 2004
WHO classification of tumours.
There is a high frequency of hereditary forms of PGLs
and PCCs (25–35 %) and these in turn, may be multi-
focal [1, 2]. Molecular genetic research to date has so far
identified multiple susceptible genes for tumours of the
paraganglia system [3–5], which can be classified into
two groups. The pseudohypoxic cluster is characterised
by constitutive activation of hypoxia inducible factors
leading to inhibition of oxidative phosphorylation and
activation of glycolytic pathway via the Warburg effect –
includes the succinate dehydrogenase (SDH) subunit B,
C, D, complex assembly factor 2 (AF2, also called SDH5)
and A, Von Hippel-Lindau disease (VHL), Hypoxia Indu-
cible Factor (HIF) Type 2 and fumarate hydratase (FH)
genes. The kinase signalling subgroup, includes charac-
teristic mutations in REarranged during Transfection
(RET) in Multiple Endocrine Neoplasia type 2 (MEN2),
Neurofibromatosis type 1 (NF1), transmembrane pro-
tein 127 (TMEM127), MYC associated factor X (MAX),
EGLN1 (PHD2), KIF1 and IDH1 [6]. Our group has re-
cently described a technique for assigning tumours into
these subcategories [7]. PCCs may coexist with other
tumour types in MEN2A, MEN2B, VHL and NF1.
Extra-adrenal PGLs may also occur in other multiple
neuroendocrine syndromes such as Carney-Stratakis dyad
and Carney’s triad.
Although most PGLs and PCCs are benign and slow
growing, metastasis or malignant degeneration can occur.
The reported rate varies but it appears that PGLs associ-
ated with the SDHB germline mutation carries a signifi-
cantly higher rate of a more aggressive behaviour locally
and developing metastatic disease [8, 9]. Sympathetic
PGLs may hypersecrete catecholamines while parasympa-
thetic PGLs are mostly non-secretory. Somatostatin cell
surface receptor (SSR) overexpression is common in neu-
roendocrine tumours including PGL and PCCs. SSR type
2 is the most commonly overexpressed [10, 11].
Molecular imaging in combination with anatomic im-
aging is often required to stage and monitor treatment
response of PGLs and PCCs and also provides informa-
tion relevant to selection of radionuclide therapy in the
context of metastatic disease. The historical molecular
imaging gold standard is with I-123 Metaiodobenzylgua-
nidine (MIBG) [12] combined with anatomic imaging
with CT or MRI. Somatostatin receptor based imaging
has also been performed with In-111 DTPA Pentetreo-
tide SPECT/CT [13]. More recently, newer radiophar-
maceuticals particularly positron emitter imaging with
PET/CTs such as with F-18 FDG or Ga-68 DOTA-
coupled peptides have been shown to have higher sensitiv-
ity and better imaging characteristics in the staging and
restaging of this disease [14]. There are currently three
DOTA-coupled peptides in clinical use (DOTATATE,
DOTANOC and DOTATOC), all showing especially
high affinity for somatostatin surface receptor type-2.
The advantages of PET/CT versus SPECT/CT and the
intricacies of SSR binding using DOTA coupled pep-
tides versus In-111 DTPA Pentetreotide have been ex-
tensively discussed elsewhere [2, 14–19] and will not be
addressed here.
We report our experience of imaging patients with
PGLs and PCCs who had both Ga-68 DOTATATE and
F-18 FDG PET/CT imaging. A subset of patients also
had I-123 SPECT/CT or I-124 MIBG PET/CT enabling
a limited comparison between the historical molecular
imaging gold standard and newer molecular imaging
techniques. Our aim was to evaluate the diagnostic util-
ity and patterns of uptake on DOTATATE and FDG in
the detection of PGL and PCC. Secondary aims were to
compare DOTATATE and FDG to MIBG, the historical
molecular imaging gold standard, assess the utility of
molecular imaging in the different germline mutations,
predicting aggressive disease and patterns of brown adi-
pose tissue (BAT) uptake on 18F FDG related to hormone
secreting tumours.
Methods
In this retrospective study, we searched our radiology in-
formation system (RIS) for patients with PGL or PCCs
who underwent both DOTATATE and FDG PET/CTs
within 6 months of one another. The study period
encompassed all patients imaged between August 2011
and November 2014. 34 patients were identified, of
whom 23 patients (13 males, 10 females, mean age 43,
range 21–74) had no changes in management in the
interval between the scans and were included in this
study. 14 patients had both DOTATATE and FDG PET/
CTs either on the same day or 1 day apart, 4 patients
had scans within 1 month and five patients had scans
within 2 to 6 months. Seven patients had I-123 MIBG
SPECT/CT and one patient had I-124 MIBG PET/CT as
part of work-up to assess suitability for I-131 MIBG
therapy. This study was approved by the institutional
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ethics review board. As a clinical practice audit, the need
for patient consent was waived.
Six patients were imaged as part of initial work-up and
staging while the remaining 15 patients had prior treat-
ments. For 13 of these patients, the DOTATATE PET
was performed, in part, to assess potential suitability for
peptide receptor radionuclide therapy (PRRT). 7 patients
had confirmed SDHB mutation, one patient each had
SDHD, SDHA, or MEN2A, three had no germline muta-
tion identified and seven were not tested. No adverse
events were observed patients after administration of
DOTATATE, FDG or MIBG.
Image acquisition and analysis
All PET/CT images were acquired on a hybrid PET/CT
device (either Biograph 64 with TrueV, Siemens Medical
Systems or Discovery 690, GE Healthcare). The injected
dose of DOTATATE was 3.1 MBq/kg with an uptake
time of between 45 to 60 min. Patients were not re-
quired to fast for the study. The injected dose of FDG
was 3.6 MBq/kg with an uptake time of 60 min. Patients
were required to fast for a minimum of 6 h and radio-
pharmaceuticals was injected if blood sugar levels were
less than 10.0 mmol/L. Planar and SPECT/CT imaging
were acquired on a hybrid SPECT/CT device (Symbia
T6, Siemens Medical Systems). Injected dose of MIBG
was approximately 340 MBq and imaging was performed
24 h later (+/− 2 h).
Any lesion demonstrating activity higher than the
physiologic uptake of the involved organ was considered a
“true” lesion unless correlative anatomic imaging suggested
non malignant or alternative pathology. PET/CT images
were evaluated qualitatively and semiquantitatively. For
lesion assessment, if there were multiple lesions in one
particular organ, the 3 lesions with the highest SUVmax
was recorded. Sites showing discordant uptake (increased
DOTATATE uptake but no FDG uptake or vice versa)
were also recorded. Qualitatively, DOTATATE uptake
intensity was graded as mild, moderate or intense cor-
responding to faint, intensity less than, equal to, or
greater than liver, respectively. The presence, intensity
and distribution of BAT uptake on FDG and adminis-
tration of alpha and/or beta blockers at the time of the
study were also recorded. BAT uptake was graded as
none, mild = present in one region (neck and supraclavicu-
lar region, thoracic paravertebral/mediastinal region, or
below the diaphragm/perinephric region) (SUVmax > 2.5),
moderate = present in two regions, and severe = present in
all three regions. I-123 MIBG images was evaluated quali-
tatively both on planar and SPECT/CT. Uptake intensity
was graded as none, mild = faint, moderate = less than or
equal to hepatic uptake and intense = higher than hepatic
uptake. The I-124 MIBG PET/CT was evaluated identi-
cally to I-123 MIBG studies.
Statistical analysis
Lesion based sensitivities were compared between
DOTATATE, FDG and MIBG. For comparison of
SUVmax difference between DOTATATE and FDG,
and between aggressive and non-aggressive patients
for DOTATATE and FDG, the Mann–Whitney test
was used.
Results
Nineteen patients had multifocal metastatic disease and
the remaining four patients had disease confined to one
site of disease (three patients with disease confined to the
primary site and one patient with oligometastatic disease).
Fifteen patients had PGLs (14 with metastatic disease and
one with disease confined to the primary site) and eight
patients had PCCs (five with metastatic disease and three
with non-metastatic PCC). Six patients (three with SDHB
germline mutation and three with negative mutation
testing) had disease progression symptomatically, bio-
chemically and on imaging within six months despite
commencement of therapy (either chemotherapy, radio-
therapy, PRRT or a combination) and were classified as
having an aggressive phenotype of the disease. In total,
104 lesions were identified in 23 patients and analysed and
the results are summarised in Tables 1 and 2.
Ga-68 DOTATATE PET/CT findings
In 100 of the 104 (96 %) lesions analysed, DOTATATE
was positive at sites of disease regardless of presence or
absence of germline mutation. Semi-quantitatively, SUV-
max ranged from 4 to 185 with a median of 21.0. Quali-
tatively, most lesions demonstrated moderate-to-high
uptake intensity with intensity greater than liver. Lesions
with lower intensities were generally at sites of low vol-
ume disease (smaller than 5 mm or not visible on ana-
tomic imaging) and, therefore, best explained by partial
volume effects.
In one patient, DOTATATE PET/CT detected a glo-
mus jugulare tumour that could not be visualised with
FDG PET/CT (Fig. 1). In other patients, although add-
itional lesions were evident on DOTATATE compared
to FDG PET/CT, this did not alter stage but merely
identified additional sites in patients with already known,
widespread metastases (Fig. 2).
The SUVmax was lower in patients with aggressive
clinical behaviour as opposed to non-aggressive cases
with median of 15.5 compared to 22.0, but the difference
was not statistically significantly (p = 0.25).
F-18 FDG PET/CT findings
FDG was positive in 95 of 104 lesions (91 %), with
SUVmax ranging from 2 to 44, median 12.5 which was
significantly less intense than 21 for DOTATATE PET/
Chang et al. Cancer Imaging  (2016) 16:22 Page 3 of 12
CT (p < 0.0001). Qualitatively, most lesions identified
demonstrated moderate-to-high uptake. There were two
patients with metastatic PGL and PCC respectively who
had liver metastases not detected on DOTATATE. In both
patients, the liver lesions were positive on FDG and nega-
tive on MIBG (Figs. 3 and 4).
Patients who had the aggressive phenotype of disease
had higher F-18 FDG SUVmax (median 20.5) compared
to patients with indolent or slowly progressive disease
(SUVmax 10.0) (p < 0.001). However, four of these patients
had an underlying SDHB germline mutation, while two
had negative testing and one was not tested. A further four
Table 1 Patient characteristics
Patient Sex Age Germline Mutation Location of Primary Location of Metastases Hormone Secreted
1 M 42 SDHB R Carotid Body Bone Adr, NorAdr
2 M 43 SDHD R Glomus Jugulare Lymph node Nil
3 M 59 SDHB R Carotid Body Bone, Lung Nil
4 M 23 Negative Retroperitoneum Lymph node NorAdr, Dop
5 F 31 MEN-2A Both Adrenals Nil Adr, NorAdr
6 F 50 Not tested L Adrenal Bone, Lymph node NorAdr
7 M 74 Not tested R Adrenal Nil Adr, NorAdr
8 M 24 SDHB Adrenal & Retroperitoneum Bone, Lymph node Unknown
9 F 63 Not Tested R Glomus Vagale Bone, Liver, Lymph node, Lung Nil
10 M 46 SDHB Unknown Bone, Lymph node NorAdr
11 F 22 Negative L Adrenal Bone, Lymph node NorAdr
12 M 40 Negative Unknown Bone, Liver, Lymph node Unknown
13 M 69 Not Tested R Carotid Body Liver, Lymph node Nil
14 M 21 SDHB R Adrenal & L Glomus Jugulare Bone, Liver, Lymph node Adr, NorAdr
15 M 35 Not Tested Unknown Bone, Liver, Lymph node Nil
16 M 66 Not tested R Carotid Body Nil Nil
17 M 20 Not tested R Adrenal Nil Adr
18 F 26 SDHB Retroperitoneum Bone, Liver, Lymph node NorAdr
19 F 49 SDHB Pelvic Lymph node Nil
20 F 68 Not avail. R Adrenal Liver, Lymph node Nil
21 F 32 SDHA R Glomus Jugulo-Tympanicum Bone NorAdr, Dop
22 F 31 SDHB L Carotid Body Bone, Liver Nil
23 F 50 Not Tested Retroperitoneum Nil NorAdr
Adr adrenaline, NorAdr noradrenaline, Dop dopamine
Table 2 Number of lesionsa detected (%)
Lesion Site Ga-68 DOTATATE F-18 FDG I-123/I-124 MIBG
Bone 41/41 37/41 3/21
Liver 14/16 16/16 3/11
Lung 5/5 5/5 1/3
Lymph Node 24/24 24/24 5/13
Primary 16/18 13/18 5/8
Total 100/104 95/104 17/56
aup the three lesions per organ were counted
Fig. 1 A 43 year-old male with SDHD germline mutation and prior
excision of multiple paragangliomas. PET imaging was performed to
characterise an equivocal mediastinal nodal abnormality identified
on CT. Ga-68 DOTATATE (a) demonstrate very intense uptake in a
right skull base glomus jugulare tumour (SUVmax = 90), which was
not visible on F-18 FDG, in part, attributable to high uptake in
physiologic cerebral activity (b). A left paratracheal abnormality in
the mediastinum showed intense DOTATATE uptake and low grade
uptake on FDG. This likely represented a further paraganglioma rather
than a metastasis. The presence of 2 tumour suggests a probable
germ-line mutation and would have warranted genetic testing if the
germ-line mutation was not already known
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patients had very high FDG uptake similar to patients with
aggressive disease but had stable disease with 1–3 year
follow-up. Three of these patients had SDHB germline
mutation suggesting metabolic reprogramming (Fig. 5).
The combined findings of FDG and DOTATATE, how-
ever, may assist in disease characterisation with high FDG
but low DOTATATE uptake being a potential indicator of
aggressive disease (Fig. 6).
I-123 and I-124 MIBG findings
MIBG was positive in substantially fewer lesions (17/56,
30 %). When positive, the majority of lesions demon-
strated moderate-to-intense MIBG uptake. The only pa-
tient in our study who had I-124 MIBG PET/CT as part
of workup for I-131 MIBG therapy was positive in 4 out
of 8 of the lesions (50 %). There may, however, be a se-
lection bias related to the high proportion of patients
presenting with metastatic disease or known SDHB
mutation. Additionally, as a tertiary oncology referral
centre, patients with strongly positive MIBG imaging,
especially in a primary lesion would be unlikely to be
referred for DOTATATE scanning.
Influence of catecholamine levels and beta-blockade on
FDG PET/CT imaging appearances
Twelve patients had documented elevated serum or
urinary catecholamines within six months of the time of
imaging with FDG PET/CT (Table 3). Five patients had
increased BAT uptake, which was severe in three cases
with intensely avid BAT uptake above and below the dia-
phragm (Fig. 6). Two patients concurrently treated with
beta (and alpha) blockade had no visible BAT uptake.
However, half of patients treated with alpha blockade
alone had visible BAT uptake.
Two of the three patients with severely increased BAT
uptake at baseline had follow-up FDG PET/CT imaging.
One patient had interval treatment with alpha/beta-
blockade and despite disease progression demonstrated
near complete resolution of BAT (Figs. 7 and 8). A sec-
ond patient had interval resection of four abdominal
PGLs, normalisation of plasma normetadrenaline and
complete resolution of BAT uptake. The BAT uptake
was most intense and extensive in those patients with
most elevated noradrenaline levels; all patients with nor-
adrenaline levels more than 8 times the upper limit of
normal (ULN) range had severe BAT uptake, whilst
there was variable BAT uptake in those patients with nor-
adrenaline levels 3–8 times ULN range. One patient had
Fig. 2 Middle-aged man with long-standing large neck carotid body
tumour on the background of SDHD-mutation, with newly diagnosed
wide-spread osseous metastatic disease on F-18 FDG (a). Ga-68
DOTATATE (b) demonstrates superior tumour-to-background contrast
with identification of greater number of metastases compared to FDG.
The disease stage (stage IV), however, is not altered by the greater
detection rate of DOTATATE PET/CT but confirms suitability for
peptide receptor radionuclide therapy
Fig. 3 65 year-old female with negative germline mutation testing. The patient had a right glomus vagale with metastatic disease to lymph
nodes, bone and liver evident on Ga-68 DOTATATE (a), F-18 FDG (b) but not I-123 MIBG (c). One of the hepatic metastases, however, was seen
on FDG but not on other imaging modalities (arrow). The lower physiologic background activity on FDG may result in increased detection rate
compared to DOTATATE in some patients
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moderate BAT uptake despite contemporaneous normal
plasma catecholamine levels, potentially reflecting
underlying physiologic BAT activity.
Discussion
In our cohort of patients, PGL and PCCs generally dem-
onstrated high uptake on both DOTATATE and FDG
PET/CT, although the intensity of uptake was significantly
greater with DOTATATE PET/CT. Combined with lower
background activity, this resulted in significantly superior
tumour contrast with DOTATATE allowing easier and
more confident diagnosis. Whilst this finding was largely
true regardless of location (head and neck versus abdo-
men) or sporadic versus inherited cases, exceptions were
found. The only site where DOTATATE had lower detec-
tion rate of lesions was in the liver, most likely due to the
high background hepatic parenchymal uptake obscuring
sites of disease. The specificity in diagnosing neuroendo-
crine tumours is also high for DOTATATE PET/CT [20],
which overexpress SSR like PGL and PCCs with conse-
quent high management impact [21]. Theranostic proper-
ties of DOTATATE also enables selection of patients
potentially suitability for PRRT with either Lu-177 or Y-90
labelled DOTATATE [22, 23]. Further, DOTATATE can
be used as a response assessment in this setting or follow-
up in patients who are undergoing treatment and does
not suffer from interactions with inhibitory medications
compared to MIBG studies. Detection rate of DOTATATE
is also much higher compared to the subgroup of our pa-
tients who had MIBG, the historical molecular imaging
gold standard. This is consistent with prior series but may
also partially reflect a selection bias in this series as de-
tailed above.
Marked overexpression of SSTR-2 cell surface expres-
sion in PGLs and PCCs was described over two decades
ago [11, 24]. It is therefore not surprising that DOTA-
TATE, which has a predominant affinity for SSTR-2, is
sensitive for imaging these tumours. Janssen et al. recently
demonstrated significantly superior detection rate of
DOTATATE PET/CT in a prospective series of 17 patients
with SDHB-related metastatic PGLs and PCCs compared
to FDG, fluorodihydroxyphenylalanine (FDOPA), fluoro-
dopamine (FDA) and CT/MRI [25]. In particular, a lesion-
based detection rate of 99 % was seen with DOTATATE
compared to 86 % for FDG PET/CT. The same group has
also demonstrated superior sensitivity of DOTATATE in
detection of head and neck paragangliomas, especially
SDHD-related tumours [26].
The higher lesional metabolic activity seen on FDG
PET/CT in cases with mutations from the pseudohy-
poxic cluster (notably including SDH germline muta-
tions) parallels the underlying biology and highlights the
ability of molecular imaging to visualise consequences of
mitochondrial mutations that result in altered glycolytic
metabolism. Succinate dehydrogenase (SDH) is a mito-
chondrial membrane bound enzyme complex that catalyzes
the oxidation of succinate to fumarate in the tricarboxylic
acid cycle (TCA cycle). Loss of SDH enzyme activity
leads to constitutive activation of hypoxia inducible factors
(HIF) regardless of oxygen levels with resultant inhibition
of oxidative phosphorylation and induction of less efficient
glycolytic pathways consistent with the Warburg effect.
Fig. 4 A 20 year old male with SDHB germline mutation and metastatic PCC. Baseline Ga-68 DOTATATE (a) and F-18 FDG (b) demonstrated metastatic
disease with a concordant pattern of uptake. The patient was treated with 3 cycles of peptide receptor radionuclide therapy for uncontrolled hypertension.
Follow-up DOTATATE and FDG imaging over a 2 year period demonstrated stable findings (c: FDG at 2 years). The high FDG-uptake was not predictive of
an aggressive phenotype and reflects changes secondary to SDHB mutation and consequent disordered oxidative phosphorylation
Chang et al. Cancer Imaging  (2016) 16:22 Page 6 of 12
The resultant metabolic reprogramming leads to very in-
tense FDG uptake may occur despite a benign differenti-
ated phenotype [27].
Our series includes some patients with SDHx-related
mutations that had lower DOTATATE uptake in more ag-
gressive cases presumably due to dedifferentiation and loss
of SSTR-expression. Lower uptake intensity similar to or
less than liver, however, was still clearly sufficient to detect
sites of disease, with the exception of hepatic metastases.
As expected, high FDG uptake is seen in aggressive meta-
static disease [14, 27] regardless of germline mutation status
and this was the case in several patients who succumbed to
the disease shortly after diagnosis. Although SDHB germ-
line mutation carriers have a higher risk of malignant de-
generation [28–30], the intense FDG avidity is also evident
in benign lesions and does not necessarily indicate aggres-
sive or dedifferentiated disease [27]. This was the case in 3
of our patients who had stable burden of disease albeit
metastatic, and did not have symptomatic or biochemical
progression with a period of 1 to 4 years follow-up. Two
patients, however, were treated with peptide receptor radio-
nuclide therapy potentially confounding this observation.
In the patient with SDHA germline mutation, the disease
progressed very slowly over 5 years despite no treatment
apart from local surgery and radiotherapy to the primary
right glomus jugulo-tympanicum at presentation. Thus,
for certain subtypes of PCC/PGLs with disordered oxi-
dative phosphorylation, FDG alone cannot characterise
the aggressiveness of disease. The combination of low
DOTATATE and high FDG uptake in these subtypes,
however, may represent a specific feature of aggressive
disease. The variation of uptake we have observed is
summarised in Table 4 and suggested key indications in
Table 5.
Fig. 5 A 25 year old female with SDHB germline mutation and metastatic PGL. Sites of disease show very high F-18 FDG uptake (left) with relative
low Ga-68 DOTATATE uptake (middle) and MIBG (right). The findings indicated lack of suitability for either radionuclide therapy with radiolabelled
DOTATATE or MIBG. The patient had a rapidly progressive disease course despite treatment with chemotherapy (combination of cyclophospha-
mide, vincristine, dacarbazine) and subsequently sunitinib. The lack high SSTR expression is unusual for a SDHB phenotype and was indicative of
de-differentiated disease with consequent aggressive phenotype
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Fig. 6 This middle-age female presented with back pain and a retroperitoneal mass on CT. F-18 FDG demonstrate moderate uptake (left), Ga-68 DOTA-
TATE was negative (middle) with only physiologic uptake in the pancreas uncinate process (green arrow) while I-123 MIBG (right) demonstrated intense
uptake. A paraganglioma was confirmed following surgical resection. Plasma and urine normetanephrine were elevated at 3728 pmol/L (N < 900) and
11.8 micromol/day (normal <2.3), respectively
Table 3 Clinical, biochemical and BAT FDG uptake characteristics of patients with elevated catecholamine levels
Age Gender Adr NorAdr Dop BAT severity SUVmax Beta-blocker Alpha-blocker
46 M 0.32 20 0.15 Severe 19 No No
23 M 0.63 15 1.1 Severe 18 No No
50 F 0.67 8.2 0.55 Severe 10 No Yes
22 F 0.02 7.5 0.54 Nil <2.5 No Yes
30 M 0.84 6.3 0.60 Mild 4.8 No Yes
26 F 0.22 5.2 N/A Nil <2.5 No Yes
50 F 0.47 4.1 0.82 Nil <2.5 Yes Yes
74 M 3.4 3.6 0.16 Nil <2.5 Yes Yes
32 F 0.30 3.1 1.2 Mild 5 No No
68 F 0.21 2.4 N/A Nil <2.5 No No
21 M 0.28 2.2 0.86 Nil <2.5 No No
31 F 1.7 1.3 N/A Nil <2.5 No Yes
Adr adrenaline, NorAdr noradrenaline, Dop dopamine, expressed as multiples of upper limit of reference range, BAT brown adipose tissue, SUVmax maximuma
standardised uptake value, N/A not available. Items abnormal are highlight in bold
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Compared to conventional molecular imaging with I-
123 MIBG, several authors have suggested the better de-
tection rate of DOTATATE [31, 32] and FDG [15, 27]
PET/CT and our results largely confirm these find-
ings. This in part is due to higher spatial resolution
of PET/CT compared to SPECT/CT. Even in the case
of I-124 MIBG imaging in one of our patients, the
number of lesions detected was lower compared to
both DOTATATE and FDG PET/CT. MIBG however,
remains an essential modality for selection of patients
for MIBG therapy.
Integration of the molecular imaging phenotype into pa-
tient management is complementary to genetic testing and
histopathology, providing disease characterisation on a
whole body scale [33]. Molecular imaging phenotype may
suggest the type of mutation and direct genetic test-
ing as mutational status is often not known at the
time of imaging. In our experience, either DOTA-
TATE or FDG PET/CT can be utilised for diagnosis
in patients with suspected PGL/PCC when mutation
status is not known but DOTATATE being theranos-
tic is far more suitable for our patient population.
Several other radiopharmaceuticals are also used to
image PGL/PCC such as F-18 FDOPA [34], F-18 FDA
and C-11 HED [35, 36]. Because our patient population is
mostly referred to us for diagnosis and consideration for
PRRT or I-131 MIBG therapy, the non-theranostic prop-
erties are major drawbacks and some radiopharmaceuti-
cals are either not readily available or have not been
approved for clinical use in Australia.
Fig. 7 Patients with SDHB-related metastatic PGL showing extensive brown adipose tissue above and below the diaphragm on F-18 FDG PET/CT
due to high circulating catecholamines (serum normetadrenaline 18 000 pmol/L, normal <900). F-18 FDG MIP (left) and axial fused PET/CT
(bottom) and MIBG (right). The peri-nephric and, to a lesser extent central para-vertebral distribution is characteristic of PCC/PGL-related
brown fat activation. Ga-68 DOTATATE (middle) clearly demonstrated an Organ of Zuckerkandl primary and several osseous metastases (botttom
middle and bottom right), and is not subject to this physiologic artefact. As well as masking potential primary tumour sites along the sympathetic chain,
the “sink effect” in brown fat limits availability of tracer for uptake in tumour sites
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Several cases demonstrated extensive activation of BAT
on FDG due to very high circulating catecholamines, with
follow-up imaging demonstrating resolution of BAT activ-
ity in two cases after successful treatment with surgery,
PRRT and alpha blockade. BAT activation is commonly
stimulated by cold exposure and inversely correlated with
body mass index, although it is also a less appreciated but
important characteristic of catecholamine secreting PGL/
PCCs [37, 38]. Given that beta-blockers are often adminis-
tered to suppress BAT uptake for repeat imaging [39], it is
critical to consider the possibility of PGL/PCC in the ap-
propriate clinical context (e.g., assessment of adrenal/
paravertebral lesion) because isolated beta-blockade may
precipitate hypertensive crisis due to unopposed alpha-
adrenergic activation. The absence of brown fat activation
in several cases despite documented high catecholamine
levels is likely explained by concurrent treatment with
alpha/beta blockers. A recent Chinese study [40] compar-
ing BAT uptake on FDG PET/CT in patients with PGL/
PCC and normal controls demonstrated a positive correl-
ation between total metanephrine levels and BAT FDG
avidity is consistent with our series.
There are several limitations to this study. This was a
retrospective analysis and a relatively small patient
population, albeit acknowledging this is a rare disease.
There is also patient selection bias as our institution per-
forms peptide receptor radionuclide therapy resulting in
a higher proportion of patients with metastatic disease
and our results may not be generalizable to patients with
non-metastatic PGL/PCC. We also did not have patients
with known VHL, TMEM127, NF1 and MAX germline
mutations, again acknowledging the rarity of some of
these mutations. Secondly, not all our patients had
MIBG studies to enable better comparison of newer mo-
lecular imaging techniques to the current molecular im-
aging gold standard in PGL and PCC imaging. Thirdly,
for ethical reasons, histopathology was not performed
on all lesions to confirm the reasons for apparent differ-
ences in DOTATATE, FDG and MIBG uptake.
Conclusion
Acknowledging the heterogenous imaging nature of PGL
and PCCs, our series suggests DOTATATE PET/CT is a
suitable first-line hybrid molecular and anatomic study
due to its theranostic properties, superior tumour con-
trast compared to FDG PET/CT and vastly superior de-
tection rate compared to MIBG planar and SPECT/CT.
Ease of preparation, lack of confounding brown fat acti-
vation and patient-friendly imaging are additional advan-
tages. Performing a staging DOTATATE PET/CT allows
clinicians to confidently diagnose or exclude the disease,
guide future management, further investigations particu-
larly germline mutation testing and avoid unnecessary
procedures or biopsies [41]. MIBG should gener-
ally only be performed if I-131 MIBG therapy is being
considered and FDG PET/CT provides additional in-
formation regarding the possibility of pseudohypoxia
cluster germline mutation, metabolic disease aggres-
siveness and directing sites for histologic analysis if
required.
Fig. 8 The same patient from Fig. 7 with baseline F-18 FDG (a)
shown prior to commencement of alpha/beta-blockade. Following
excision of the primary site (red arrow) there was marked progres-
sion of metastatic disease on FDG (b) with concordant biochemical
progression. Despite rising normetadrenaline levels (>100,000pmol/L
compared to 18,000pmol/L at baseline) brown fat activation is not
visualised following commencement of alpha/beta-blockade
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amay diminish in small subgroup of patients with aggressive phenotype
Table 5 Key indications for molecular imaging in PCC/PGL
▪ Diagnosis and localisation of adrenal-and extra-adrenal PCC/PGL in
patients with elevated catecholamine levels.
▪ Staging of patients prior to surgical resection to exclude metastatic or
additional primary sites of disease.
▪ Selection of patients for radionuclide therapy with 177Lu/90Y
radiolabelled DOTATATE or 131I-MIBG therapy.
▪ Response assessment following chemotherapy or targeted therapies.
▪ Surveillance of patients with inherited mutations such as SDHxor VHL
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